Listed

Edgewise Therapeutics, Inc.

EWTXNasdaqCIK 1710072HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$61.9m, Q2 FY2026
Net income−$57.3m, Q2 FY2026
Edgewise Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m23.8Research and development, Q3 FY2023, three months to 2023-09-30$23.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure27.7Research and development, Q4 FY2023, three months to 2023-12-31$27.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure27.7Research and development, Q1 FY2024, three months to 2024-03-31$27.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure30.7Research and development, Q2 FY2024, three months to 2024-06-30$30.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure32.2Research and development, Q3 FY2024, three months to 2024-09-30$32.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure36.4Research and development, Q4 FY2024, three months to 2024-12-31$36.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure36.8Research and development, Q1 FY2025, three months to 2025-03-31$36.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure33.6Research and development, Q2 FY2025, three months to 2025-06-30$33.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure37.5Research and development, Q3 FY2025, three months to 2025-09-30$37.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure43.6Research and development, Q4 FY2025, three months to 2025-12-31$43.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure42.7Research and development, Q1 FY2026, three months to 2026-03-31$42.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure47.5Research and development, Q2 FY2026, three months to 2026-06-30$47.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure
Operating income$m(29.5)Operating income, Q3 FY2023, three months to 2023-09-30−$29.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure(33.9)Operating income, Q4 FY2023, three months to 2023-12-31−$33.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure(34.8)Operating income, Q1 FY2024, three months to 2024-03-31−$34.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure(38.1)Operating income, Q2 FY2024, three months to 2024-06-30−$38.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure(40.4)Operating income, Q3 FY2024, three months to 2024-09-30−$40.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure(45.5)Operating income, Q4 FY2024, three months to 2024-12-31−$45.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure(46.0)Operating income, Q1 FY2025, three months to 2025-03-31−$46.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure(42.6)Operating income, Q2 FY2025, three months to 2025-06-30−$42.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure(46.9)Operating income, Q3 FY2025, three months to 2025-09-30−$46.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure(56.0)Operating income, Q4 FY2025, three months to 2025-12-31−$56.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure(54.1)Operating income, Q1 FY2026, three months to 2026-03-31−$54.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure(61.9)Operating income, Q2 FY2026, three months to 2026-06-30−$61.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure
Net income$m(25.7)Net income, Q3 FY2023, three months to 2023-09-30−$25.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure(30.1)Net income, Q4 FY2023, three months to 2023-12-31−$30.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure(28.5)Net income, Q1 FY2024, three months to 2024-03-31−$28.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure(31.5)Net income, Q2 FY2024, three months to 2024-06-30−$31.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure(34.1)Net income, Q3 FY2024, three months to 2024-09-30−$34.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure(39.7)Net income, Q4 FY2024, three months to 2024-12-31−$39.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure(40.8)Net income, Q1 FY2025, three months to 2025-03-31−$40.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure(36.1)Net income, Q2 FY2025, three months to 2025-06-30−$36.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure(40.7)Net income, Q3 FY2025, three months to 2025-09-30−$40.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure(50.2)Net income, Q4 FY2025, three months to 2025-12-31−$50.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure(49.0)Net income, Q1 FY2026, three months to 2026-03-31−$49.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure(57.3)Net income, Q2 FY2026, three months to 2026-06-30−$57.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure
Diluted EPS$ per share(0.41)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figurenot reported(0.33)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure(0.34)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure(0.36)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figurenot reported(0.43)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure(0.34)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure(0.39)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figurenot reported(0.46)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure(0.53)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure
Basic EPS$ per share(0.41)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figurenot reported(0.33)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.33 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure(0.34)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure(0.36)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figurenot reported(0.43)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.43 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure(0.34)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure(0.39)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figurenot reported(0.46)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.46 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure(0.53)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.53 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure

Balance sheet

Cash and equivalents$72.3m, Q2 FY2026
Shareholders' equity$448.1m, Q2 FY2026
Edgewise Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m33.0Cash and equivalents, Q3 FY2023, at 2023-09-30$33.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001558370-23-018427.Report this figure86.1Cash and equivalents, FY2023, at 2023-12-31$86.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-03, accession 0001558370-25-002006.Report this figure30.3Cash and equivalents, Q1 FY2024, at 2024-03-31$30.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001544784-24-000056.Report this figure43.5Cash and equivalents, Q2 FY2024, at 2024-06-30$43.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001558370-24-011477.Report this figure44.8Cash and equivalents, Q3 FY2024, at 2024-09-30$44.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure41.7Cash and equivalents, FY2024, at 2024-12-31$41.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001104659-26-020112.Report this figure49.9Cash and equivalents, Q1 FY2025, at 2025-03-31$49.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure43.4Cash and equivalents, Q2 FY2025, at 2025-06-30$43.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure46.0Cash and equivalents, Q3 FY2025, at 2025-09-30$46.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure61.1Cash and equivalents, FY2025, at 2025-12-31$61.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure33.2Cash and equivalents, Q1 FY2026, at 2026-03-31$33.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure72.3Cash and equivalents, Q2 FY2026, at 2026-06-30$72.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure
Current assets$m298Current assets, Q3 FY2023, at 2023-09-30$297.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001558370-23-018427.Report this figure327Current assets, FY2023, at 2023-12-31$327.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-03, accession 0001558370-25-002006.Report this figure541Current assets, Q1 FY2024, at 2024-03-31$541.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001544784-24-000056.Report this figure519Current assets, Q2 FY2024, at 2024-06-30$519.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001558370-24-011477.Report this figure499Current assets, Q3 FY2024, at 2024-09-30$499.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure475Current assets, FY2024, at 2024-12-31$475.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001104659-26-020112.Report this figure443Current assets, Q1 FY2025, at 2025-03-31$443.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure603Current assets, Q2 FY2025, at 2025-06-30$603.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure574Current assets, Q3 FY2025, at 2025-09-30$573.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure543Current assets, FY2025, at 2025-12-31$543.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure510Current assets, Q1 FY2026, at 2026-03-31$509.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure472Current assets, Q2 FY2026, at 2026-06-30$471.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure
Total assets$m311Total assets, Q3 FY2023, at 2023-09-30$311.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001558370-23-018427.Report this figure340Total assets, FY2023, at 2023-12-31$340.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-03, accession 0001558370-25-002006.Report this figure554Total assets, Q1 FY2024, at 2024-03-31$553.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001544784-24-000056.Report this figure532Total assets, Q2 FY2024, at 2024-06-30$531.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001558370-24-011477.Report this figure511Total assets, Q3 FY2024, at 2024-09-30$511.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure487Total assets, FY2024, at 2024-12-31$486.8m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001104659-26-020112.Report this figure454Total assets, Q1 FY2025, at 2025-03-31$454.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure613Total assets, Q2 FY2025, at 2025-06-30$613.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure583Total assets, Q3 FY2025, at 2025-09-30$583.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure553Total assets, FY2025, at 2025-12-31$552.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure519Total assets, Q1 FY2026, at 2026-03-31$518.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure480Total assets, Q2 FY2026, at 2026-06-30$479.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure
Current liabilities$m16.3Current liabilities, Q3 FY2023, at 2023-09-30$16.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001558370-23-018427.Report this figure16.8Current liabilities, FY2023, at 2023-12-31$16.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-03, accession 0001558370-25-002006.Report this figure14.6Current liabilities, Q1 FY2024, at 2024-03-31$14.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001544784-24-000056.Report this figure17.2Current liabilities, Q2 FY2024, at 2024-06-30$17.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001558370-24-011477.Report this figure19.0Current liabilities, Q3 FY2024, at 2024-09-30$19.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure23.9Current liabilities, FY2024, at 2024-12-31$23.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001104659-26-020112.Report this figure21.1Current liabilities, Q1 FY2025, at 2025-03-31$21.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure20.9Current liabilities, Q2 FY2025, at 2025-06-30$20.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure21.6Current liabilities, Q3 FY2025, at 2025-09-30$21.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure27.4Current liabilities, FY2025, at 2025-12-31$27.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure22.5Current liabilities, Q1 FY2026, at 2026-03-31$22.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure29.0Current liabilities, Q2 FY2026, at 2026-06-30$29.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure
Total liabilities$m20.9Total liabilities, Q3 FY2023, at 2023-09-30$20.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001558370-23-018427.Report this figure21.2Total liabilities, FY2023, at 2023-12-31$21.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-03, accession 0001558370-25-002006.Report this figure18.9Total liabilities, Q1 FY2024, at 2024-03-31$18.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001544784-24-000056.Report this figure21.2Total liabilities, Q2 FY2024, at 2024-06-30$21.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001558370-24-011477.Report this figure22.4Total liabilities, Q3 FY2024, at 2024-09-30$22.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure27.6Total liabilities, FY2024, at 2024-12-31$27.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001104659-26-020112.Report this figure24.7Total liabilities, Q1 FY2025, at 2025-03-31$24.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure24.3Total liabilities, Q2 FY2025, at 2025-06-30$24.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure24.8Total liabilities, Q3 FY2025, at 2025-09-30$24.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure30.3Total liabilities, FY2025, at 2025-12-31$30.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure25.3Total liabilities, Q1 FY2026, at 2026-03-31$25.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure31.6Total liabilities, Q2 FY2026, at 2026-06-30$31.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m290Shareholders' equity, Q3 FY2023, at 2023-09-30$290.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure319Shareholders' equity, FY2023, at 2023-12-31$318.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001104659-26-020112.Report this figure535Shareholders' equity, Q1 FY2024, at 2024-03-31$534.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure510Shareholders' equity, Q2 FY2024, at 2024-06-30$510.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure489Shareholders' equity, Q3 FY2024, at 2024-09-30$488.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure459Shareholders' equity, FY2024, at 2024-12-31$459.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure430Shareholders' equity, Q1 FY2025, at 2025-03-31$429.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure589Shareholders' equity, Q2 FY2025, at 2025-06-30$589.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure559Shareholders' equity, Q3 FY2025, at 2025-09-30$558.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure522Shareholders' equity, FY2025, at 2025-12-31$522.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure493Shareholders' equity, Q1 FY2026, at 2026-03-31$493.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure448Shareholders' equity, Q2 FY2026, at 2026-06-30$448.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure

Cash flow

Operating cash flow−$42.5m, Q2 FY2026
Capital expenditure$32.0k, Q2 FY2026
Edgewise Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(22.1)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$22.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0001558370-24-014762. Derived: 9-month figure less the 6-month figure.Report this figure(26.8)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$26.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure(28.6)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$28.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure(26.1)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$26.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001558370-25-010655. Derived: 6-month figure less the 3-month figure.Report this figure(27.4)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$27.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107427. Derived: 9-month figure less the 6-month figure.Report this figure(27.0)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$27.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure(37.9)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$37.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure(32.6)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$32.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091670. Derived: 6-month figure less the 3-month figure.Report this figure(34.8)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$34.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107427. Derived: 9-month figure less the 6-month figure.Report this figure(38.6)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$38.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure(42.5)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$42.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure(42.5)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$42.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091670. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.5Capital expenditure, Q3 FY2023, three months to 2023-09-30$457.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-11-09, accession 0001558370-23-018427. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2023, three months to 2023-12-31$161.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2024, three months to 2024-03-31$297.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-05-09, accession 0001544784-24-000056.Report this figure0.2Capital expenditure, Q2 FY2024, three months to 2024-06-30$221.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-08-08, accession 0001558370-24-011477. Derived: 6-month figure less the 3-month figure.Report this figure0.5Capital expenditure, Q3 FY2024, three months to 2024-09-30$520.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107427. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2024, three months to 2024-12-31$274.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$44.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$50.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091670. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$89.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107427. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$73.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020112. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2026, three months to 2026-03-31$260.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$32.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091670. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)107.67m, Q2 FY2026
Edgewise Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares51.8Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3051,844,904 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001558370-23-018427.Report this figure63.3Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3163,265,800 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001544784-24-000056.Report this figure63.4Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3063,380,430 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001558370-24-011477.Report this figure63.5Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3063,459,560 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0001558370-24-014762.Report this figure87.6Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3187,567,307 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001558370-25-006857.Report this figure93.5Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3093,515,356 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001558370-25-010655.Report this figure93.8Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3093,813,346 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure95.1Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3195,130,053 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure105Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30104,940,493 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure105Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30105,492,779 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001104659-25-107427.Report this figure107Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31107,116,709 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001104659-26-056713.Report this figure108Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30107,669,774 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure

Shares outstanding: 108.60mShares outstanding, period not labelled, at 2026-07-31108,604,129 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001104659-26-091670.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.